FDA on BPC-157: where compounding stands now
FDA's late-2023 decision on BPC-157 closed the 503A compounding pathway. Here's what changed, what it means, and what the supply chain looks like now.
May 7, 2026 · 4 min read
In November 2023, the FDA declined to add BPC-157 to the 503A bulks list — the federally-maintained list of substances that compounding pharmacies are permitted to use in prescription compounded preparations. The decision closed the most legitimate supply pathway for BPC-157 in the United States and pushed the peptide back into the research-chemical market.
This piece walks through what 503A is, what the FDA decision actually said, and what the supply landscape looks like now.
What 503A compounding is
Under section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies are permitted to compound medications for individual patients with a valid prescription. To use a particular bulk substance, that substance must either:
- Be a component of an FDA-approved drug, OR
- Appear on the FDA's 503A bulks list
The bulks list is reviewed by FDA's Pharmacy Compounding Advisory Committee (PCAC), which considers nominations from pharmacies and other stakeholders.
What the BPC-157 decision said
PCAC reviewed BPC-157 and recommended against adding it to the 503A list. FDA accepted the recommendation. The substantive concerns cited:
- Limited human safety data. The clinical record for BPC-157 in humans is thin — small case series, no large RCTs.
- Unclear pharmacokinetics. Absorption, distribution, metabolism, and excretion in humans aren't well-characterized.
- Manufacturing standardization issues. Identity, purity, and contamination concerns across the supply.
- No clearly-defined therapeutic indication. Without an established use, benefit-risk evaluation is difficult.
The decision did not declare BPC-157 unsafe per se — it declared the data insufficient to support compounding. That distinction matters for how the peptide is regulated going forward.
What changed
Before the decision, some 503A and 503B compounding pharmacies were producing BPC-157 for prescription use. After the decision:
- Compounded BPC-157 is no longer legal in the US under 503A
- Pharmacies that continued have faced warning letters
- Patient access through prescription channels has effectively ended
- The supply has shifted entirely to research-chemical vendors
There is no FDA-approved BPC-157 product. There never has been. The 503A compounding route was the closest BPC-157 ever came to a regulated supply chain, and it's now closed.
What the supply chain looks like now
With prescription compounding off the table, BPC-157 in the US is sold under one of three labels:
| Label | Reality |
|---|---|
| "Research chemical, not for human use" | Standard research-chem disclaimer; the dominant model |
| "Cosmetic" or "topical" | Some vendors reframe to dodge regulatory questions; the product is functionally the same |
| Underground prescription-style | Pharmacies in non-US jurisdictions sometimes ship to US addresses; legal status varies |
The majority of US BPC-157 use today is research-chem-grade, sourced from either domestic vendors or international (often Chinese) manufacturers. Quality varies dramatically. Vendors that publish third-party Certificates of Analysis are the safer end of the spectrum.
What this means for users
The practical consequences:
- No prescription pathway. A clinician cannot legally write a BPC-157 prescription for compounding in the US.
- Research-chem labels carry meaning. "Research chemical, not for human use" is the legal status, not a marketing convention.
- Supply quality is the single biggest variable. A vial of BPC-157 from a vendor with rigorous COAs is materially different from one with no testing.
- Long-term safety is still open. The FDA decision didn't change that — but it did remove a regulatory check on vendor quality.
For users running BPC-157, the FDA decision doesn't change the protocols but does change the sourcing reality. The vendor-evaluation framework matters more than ever — see vendor quality checks.
What about TB-500 and other peptides?
TB-500 has not gone through a comparable FDA review. It exists in the same research-chemical-only zone but without the formal rejection. Whether TB-500 receives the same scrutiny in coming years is an open question.
For GH secretagogues, the picture is more varied:
- Tesamorelin is FDA-approved (for HIV-associated lipodystrophy)
- Sermorelin is sold by some compounding pharmacies (had been on a separate FDA-approved list historically)
- Ipamorelin, CJC-1295, MK-677 are research-chemical-only
What to watch
- Whether FDA reviews additional peptides under the same framework
- Whether DEA scheduling actions affect any strength peptides (precedent exists for similar compounds)
- Whether state-level compounding regulators take divergent positions
- Whether any vendor moves toward a formal IND (Investigational New Drug) application — the most legitimate path back
Sources
Sources